These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Insoluble wild-type and protease-resistant mutant prion protein in brains of patients with inherited prion disease. Gabizon R; Telling G; Meiner Z; Halimi M; Kahana I; Prusiner SB Nat Med; 1996 Jan; 2(1):59-64. PubMed ID: 8564843 [TBL] [Abstract][Full Text] [Related]
23. In vitro amplification of scrapie and chronic wasting disease PrP(res) using baculovirus-expressed recombinant PrP as substrate. Faburay B; Tark D; Kanthasamy AG; Richt JA Prion; 2014; 8(6):393-403. PubMed ID: 25495764 [TBL] [Abstract][Full Text] [Related]
24. Intracellular accumulation of the cellular prion protein after mutagenesis of its Asn-linked glycosylation sites. Rogers M; Taraboulos A; Scott M; Groth D; Prusiner SB Glycobiology; 1990 Sep; 1(1):101-9. PubMed ID: 1983782 [TBL] [Abstract][Full Text] [Related]
25. The interaction of humic substances with the human prion protein fragment 90-231 affects its protease K resistance and cell internalization. Corsaro A; Anselmi C; Polano M; Aceto A; Florio T; De Nobili M J Biol Regul Homeost Agents; 2010; 24(1):27-39. PubMed ID: 20385069 [TBL] [Abstract][Full Text] [Related]
26. Biochemical Characterization of Prions. Fiorini M; Bongianni M; Monaco S; Zanusso G Prog Mol Biol Transl Sci; 2017; 150():389-407. PubMed ID: 28838671 [TBL] [Abstract][Full Text] [Related]
27. Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Kocisko DA; Priola SA; Raymond GJ; Chesebro B; Lansbury PT; Caughey B Proc Natl Acad Sci U S A; 1995 Apr; 92(9):3923-7. PubMed ID: 7732006 [TBL] [Abstract][Full Text] [Related]
28. Distance of sequons to the C-terminus influences the cellular N-glycosylation of the prion protein. Walmsley AR; Hooper NM Biochem J; 2003 Feb; 370(Pt 1):351-5. PubMed ID: 12460122 [TBL] [Abstract][Full Text] [Related]
29. Knockdown of prion protein (PrP) by RNA interference weakens the protective activity of wild-type PrP against copper ion and antagonizes the cytotoxicity of fCJD-associated PrP mutants in cultured cells. Wang ZY; Tian C; Jing YY; Gong HS; Guo Y; Shi Q; Chen C; Zhu SY; Dong XP Int J Mol Med; 2011 Sep; 28(3):413-21. PubMed ID: 21537833 [TBL] [Abstract][Full Text] [Related]
30. Recombinant human prion protein mutants huPrP D178N/M129 (FFI) and huPrP+9OR (fCJD) reveal proteinase K resistance. Gauczynski S; Krasemann S; Bodemer W; Weiss S J Cell Sci; 2002 Nov; 115(Pt 21):4025-36. PubMed ID: 12356908 [TBL] [Abstract][Full Text] [Related]
31. Identification of novel proteinase K-resistant C-terminal fragments of PrP in Creutzfeldt-Jakob disease. Zou WQ; Capellari S; Parchi P; Sy MS; Gambetti P; Chen SG J Biol Chem; 2003 Oct; 278(42):40429-36. PubMed ID: 12917418 [TBL] [Abstract][Full Text] [Related]
32. Phospholipids influence the aggregation of recombinant ovine prions. From rapid extensive aggregation to amyloidogenic conversion. Tsiroulnikov K; Shchutskaya Y; Muronetz V; Chobert JM; Haertlé T Biochim Biophys Acta; 2009 Mar; 1794(3):506-11. PubMed ID: 19124088 [TBL] [Abstract][Full Text] [Related]
33. Familial prion disease mutation alters the secondary structure of recombinant mouse prion protein: implications for the mechanism of prion formation. Cappai R; Stewart L; Jobling MF; Thyer JM; White AR; Beyreuther K; Collins SJ; Masters CL; Barrow CJ Biochemistry; 1999 Mar; 38(11):3280-4. PubMed ID: 10079070 [TBL] [Abstract][Full Text] [Related]
34. Deletion of beta-strand and alpha-helix secondary structure in normal prion protein inhibits formation of its protease-resistant isoform. Vorberg I; Chan K; Priola SA J Virol; 2001 Nov; 75(21):10024-32. PubMed ID: 11581371 [TBL] [Abstract][Full Text] [Related]
35. Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres. Kim NH; Choi JK; Jeong BH; Kim JI; Kwon MS; Carp RI; Kim YS FASEB J; 2005 May; 19(7):783-5. PubMed ID: 15758042 [TBL] [Abstract][Full Text] [Related]
36. Characterization of the F198S prion protein mutation: enhanced glycosylation and defective refolding. Zaidi SI; Richardson SL; Capellari S; Song L; Smith MA; Ghetti B; Sy MS; Gambetti P; Petersen RB J Alzheimers Dis; 2005 Apr; 7(2):159-71; discussion 173-80. PubMed ID: 15851854 [TBL] [Abstract][Full Text] [Related]
37. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Selvaggini C; De Gioia L; Cantù L; Ghibaudi E; Diomede L; Passerini F; Forloni G; Bugiani O; Tagliavini F; Salmona M Biochem Biophys Res Commun; 1993 Aug; 194(3):1380-6. PubMed ID: 8102526 [TBL] [Abstract][Full Text] [Related]
38. Protease resistance of infectious prions is suppressed by removal of a single atom in the cellular prion protein. Leske H; Hornemann S; Herrmann US; Zhu C; Dametto P; Li B; Laferriere F; Polymenidou M; Pelczar P; Reimann RR; Schwarz P; Rushing EJ; Wüthrich K; Aguzzi A PLoS One; 2017; 12(2):e0170503. PubMed ID: 28207746 [TBL] [Abstract][Full Text] [Related]
39. Attempts to convert the cellular prion protein into the scrapie isoform in cell-free systems. Raeber AJ; Borchelt DR; Scott M; Prusiner SB J Virol; 1992 Oct; 66(10):6155-63. PubMed ID: 1356161 [TBL] [Abstract][Full Text] [Related]
40. Properties and pathogenicity of prion-derived peptides. Vassallo N Protein Pept Lett; 2009; 16(3):230-8. PubMed ID: 19275735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]